 "India has about 400 million children, of whom nearly 60 per cent, or 240 million, have already developed antibodies")
The approval for Bharat Biotech’s Covaxin for use in children as young as two years may be some time away with India considering a phased roll-out of the vaccine for them.
India’s drug regulator is carefully examining the recommendation by the expert panel and evaluating several factors, sources close to the development said. The panel last week recommended granting emergency use authorisation to the vaccine for children in the 2-18 years age group.
“There are several factors that are being considered by the Central Drugs Standard Control Organisation (CDSCO) like what is the performance of the vaccine in young adults (18 years
